Finance

Lists
Outlook: 63.3% bullish·3.3% bearish
Go to analysis
INO:NASDAQ
Inovio Pharmaceuticals Inc
US$ १.४६
-१.०२%
(-०.०१५) 1D
US$ १.४१
-३.४२% (-०.०५०)
After hours
Closed: नोभेम्बर १२, १६:००:०१ GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INO...
Open
US$ १.४४
High
US$ १.५३
Low
US$ १.३३
Mkt. cap
२७.२५ करोड
Avg. vol.
१.९१ करोड
Volume
०.००
52-wk high
US$ २.७२
52-wk low
US$ ०.५६
EPS
-US$ १.१७
Beta
१.७१
Shares outstanding
१८.७३ करोड
No. of employees
११२
Open
US$ १.४४
High
US$ १.५३
Low
US$ १.३३
Mkt. cap
२७.२५ करोड
Avg. vol.
१.९१ करोड
Volume
०.००
52-wk high
US$ २.७२
52-wk low
US$ ०.५६
EPS
-US$ १.१७
Beta
१.७१
Shares outstanding
१८.७३ करोड
No. of employees
११२
News stories
From web sources and news partners
News Corp
News Corp
·
१० घण्टा पहिले
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
MarketWatch
MarketWatch
·
१० घण्टा पहिले
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors
GuruFocus
GuruFocus
·
२१ घण्टा पहिले
Inovio Pharmaceuticals Inc (INO) (Q3 2026) Earnings Call Highlig
Yahoo Finance
Yahoo Finance
·
१ दिन पहिले
Inovio Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
Profile
Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development. Wikipedia
About Inovio Pharmaceuticals Inc
CEOJacqueline Shea
Employees११२
Founded१९९९
Headquarters-
SectorHealth Care
Industry-
Websiteinovio.com
Analyst ratings
Based on 3 analysts giving stock ratings to INO in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INO in the last 3 months.
Highest
Current US$ १.४६
US$ ८.०० (+४४७.९५%)
Average
US$ ६.३३ (+३३३.५६%)
Lowest
US$ ५.०० (+२४२.४७%)
Analyst
Recommendation
Action
Price target
Projected
Date
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
US$ ५.००
+२४२.५%
11/12/2026
Edward Tenthoff
Piper Sandler
Buy
Reiterated
US$ ६.००
+३११%
11/11/2026
Roger Song
Jefferies
Buy
Reiterated
US$ ८.००
+४४७.९%
11/06/2026
Hartaj Singh
Oppenheimer
Buy
Maintained
US$ १३.००
+७९०.४%
11/11/2025
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
-
-
-
-
Cost of goods sold
१.३३ करोड
१.०३ करोड
१.४१ करोड
१.०८ करोड
Cost of revenue
१.३३ करोड
१.०३ करोड
१.४१ करोड
१.०८ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
७८.७७ लाख
७२.१५ लाख
७८.८० लाख
७७.९८ लाख
Operating expense
७८.७७ लाख
७२.१५ लाख
७८.८० लाख
७७.९८ लाख
Total operating expenses
२.१२ करोड
१.७५ करोड
२.१९ करोड
१.८६ करोड
Operating income
-२.१२ करोड
-१.७५ करोड
-२.१९ करोड
-१.८६ करोड
Other non operating income
-२.४३ करोड
२.१२ करोड
४१.३७ लाख
१.२७ करोड
EBT including unusual items
-४.५५ करोड
३७.६५ लाख
-१.९७ करोड
-६०.१२ लाख
EBT excluding unusual items
-४.५५ करोड
३७.५५ लाख
-१.९५ करोड
-५५.३३ लाख
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-४.५५ करोड
३७.६५ लाख
-१.९७ करोड
-६०.१२ लाख
Net profit margin
-
-
-
-
Earnings per share
-०.८७
-०.२८
-०.३१
-०.२४
Interest and investment income
५.५२ लाख
४.४९ लाख
४.४० लाख
३.६४ लाख
Interest expense
-
-
-
-
Net interest expenses
५.५२ लाख
४.४९ लाख
४.४० लाख
३.६४ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-२.०९ करोड
-१.७१ करोड
-२.१६ करोड
-१.८३ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू